机译:Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments
Univ Rennes, CHU Rennes, INSERM,UMR S 1085, EHESP,Irset Inst Rech Sante Environm & Travail, F-35000;
Aix Marseille Univ, Hop La Timone, AP HM,Lab Pharmacocinet & Toxicol, UMR Emergence Pathol Virales;
CHU Nantes, Clin Pharmacol Dept, F-44093 Nantes 1, FranceCHU Angers, Serv Pharmacol Toxicol & Pharmacovigilance, F-49100 Angers, FranceUniv Catholique Louvain UCL, Integrated Pharmacometr Pharmacogen & Pharmacokin, Louvain Drug ResAgence Natl Securite Medicaments & Prod Sante, Med Interact Unit, F-93200 St Denis, FranceUniv Toulouse, Toulouse Univ Hosp, Fac Med,INSERM,UMR 1027,CIC 1426, Dept Med & Clin Pharmacol,CtrCHU Tours, Lab Biochim & Biol Mol, F-37044 Tours, FranceCroix Rousse Hosp, Pharm, F-69005 Lyon, France;
adverse events; hydroxychloroquine; lopinavir; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring;